Pfizer, Inc.

Pfizer Inc. develops and sells biopharmaceutical products globally. The company offers medicines and vaccines in various therapeutic areas. Products include Eliquis, Nurtec ODT/Vydura, Zavzpret, and Comirnaty brands. Pfizer also provides biosimilars for chronic immune and inflammatory diseases under Xeljanz brand. The company serves wholesalers, retailers, hospitals, clinics, and pharmacies. It has collaboration agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE. Founded in 1849, Pfizer is headquartered in New York City.

Overview

Sector

Pharmaceutical

Target Price

31.1 BRL

Current Price

24.2 BRL

Potential

-18%

Strengths

Current Price to Earnings Ratio (16.89) is lower than the sector mean (81.73).
Price to book ratio (1.54) is lower than the sector mean (8.32).
EV/EBITDA (8.45) is lower than the sector mean (21.51).
EV/EBIT (17.83) is lower than the sector mean.
Price to free cash flow (13.79) is lower than the sector mean.
Strong EBITDA Margin of 36.88%.

Weaknesses

The company has high debt. Net Debt to EBITDA Ratio (2.67) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (8.39%) is significantly lower than the sector mean (16.32%).

Key Financial Data

Indicator	Value
PER	8.0
EV/EBITDA	5.6
Price/Free Cash Flow'	7.0
ROIC	13.1%
Net Debt/EBITDA	2.3